Table 2.
The comparison of fetal outcomes of autoimmune-associated first-degree AVB diagnosed initially between treated cases and untreated cases.
| Characterizes | Treated group (n = 20, 41.67%) | Untreated group (n = 28, 58.33%) | P-value |
|---|---|---|---|
| Prenatal outcomes | |||
| Conversation to sinus rhythm | 13 (65.00%) | 16 (57.14%) | 0.583 |
| Persistence of first-degree AVB | 6 (30.00%) | 10 (35.71%) | 0.679 |
| Progression to second-/high-degree AVB | 0 | 0 | – |
| Progression to third-degree AVB | 1 (5.00%) | 1 (3.57) | 1.000 |
| Death in utero | 0 | 0 | – |
| Alive but unknown details | 0 | 1 (3.57%) | – |
| Adverse effects on fetus | 2 (10.00%) | – | – |
| Postnatal outcomes | |||
| Sinus rhythm | 14 (70.00%) | 17 (60.71%) | 0.507 |
| First-degree AVB | 4 (20.00%) | 3 (10.71%) | 0.429 |
| Second-/high-degree AVB | 0 | 0 | – |
| Third-degree AVB | 1 (5.00%) | 1 (3.57%) | 1.000 |
| Death due to AVB or AVB therapy | 0 | 0 | – |
| Alive but unknown details in original study | 1 (5.00%) | 7 (25.00%) | – |
AVB, atrioventricular block.